###begin article-title 0
The Pronounced Th17 Profile in Systemic Sclerosis (SSc) Together with Intracellular Expression of TGFbeta and IFNgamma Distinguishes SSc Phenotypes
###end article-title 0
###begin p 1
Conceived and designed the experiments: TR RH DW EL RL. Performed the experiments: TR LvB JB AH EL RL. Analyzed the data: TR LvB JB DW YD RS EL RL. Contributed reagents/materials/analysis tools: TR AH RH YD EL RL. Wrote the paper: TR LvB JB RH DW YD RS EL RL.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Systemic sclerosis (SSc) is an autoimmune disease where controversy on Th1/Th2 balance dominates. We investigated whether the recently discovered Th17 pattern was present in SSc.
###end p 3
###begin title 4
Methodology and Principal Findings
###end title 4
###begin p 5
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 599 607 <span type="species:ncbi:9606">patients</span>
###xml 703 711 <span type="species:ncbi:9606">patients</span>
###xml 1026 1034 <span type="species:ncbi:9606">patients</span>
Patients were subdivided as having limited cutaneous SSc (lcSSc, n = 12) or diffuse cutaneous SSc (dcSSc, n = 24). A further arbitrary subdivision was made between early dcSSc (n = 11) and late dcSSc (n = 13) based upon the duration of disease. As a comparator group 14 healthy controls were studied. CD3+ cells were isolated using FACS and subsequently studied for the expression of CD4, CD8, CD25, CD45Ro, CD45Ra, IL-23, GITR, CD69 and intracellular expression of IL-17, TGFbeta and IFNgamma using flow cytometry. Levels of IL-17, IL-6, IL-1alpha and IL-23 were measured using Bioplex assays. SSc patients had more and more activated CD4+ cells. In addition, CD4, CD45Ro and CD45Ra cells from all SSc patients highly expressed the IL23R, which was associated with a higher IL-17 expression as well. In contrast, IFNgamma and TGFbeta were selectively up regulated in SSc subsets. In line with these observation, circulating levels of IL-17 inducing cytokines IL-6, IL-23 and IL-1alpha were increased in all or subsets of SSc patients.
###end p 5
###begin title 6
Conclusion and Significance
###end title 6
###begin p 7
###xml 90 98 <span type="species:ncbi:9606">patients</span>
The combination of IL-17, IFNgamma and TGFbeta levels in CD45Ro and CD45Ra cells from SSc patients is useful to distinguish between lSSc, ldSSc or edSSc. Blocking Th17 inducing cytokines such as IL-6 and IL-23 may provide a useful tool to intervene in the progression of SSc.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 664 667 664 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Hussein1">[1]</xref>
###xml 669 672 669 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Gustafsson1">[2]</xref>
###xml 729 732 721 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Riccieri1">[3]</xref>
###xml 839 842 831 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Hussein1">[1]</xref>
###xml 844 847 836 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Kalogerou1">[4]</xref>
###xml 849 852 841 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Parel1">[5]</xref>
###xml 975 978 967 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-DelGaldo1">[6]</xref>
###xml 980 983 972 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Fujii1">[7]</xref>
###xml 579 587 <span type="species:ncbi:9606">patients</span>
###xml 655 663 <span type="species:ncbi:9606">patients</span>
###xml 770 778 <span type="species:ncbi:9606">patients</span>
Systemic Sclerosis (SSc) is a complex inflammatory autoimmune disease characterized by excessive deposition of matrix molecules, leading to fibrosis of multiple organs including the skin, lungs, heart and gastrointestinal tract, and often leading to severe morbidity and premature death. Although the role of immune dysfunction in the pathogenesis of SSc is generally accepted, the exact pathways that cause immune dysfunction in SSc remain to be elucidated. Alterations in cellular immunity are typified by aberrant T cell biology both in the skin as well as circulation of SSc patients. For example, CD4+ T cells are increased in the circulation of SSc patients [1], [2] whereas NKT cells and gamma/delta T cells are decreased [3]. In addition, lesional skin from SSc patients displays various features consistent with T cell activation [1], [4], [5]. Finally, T cell biology was altered in SSc in that the secretion of various inflammatory mediators is markedly increased [6], [7].
###end p 9
###begin p 10
###xml 997 1000 976 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Annunziato1">[8]</xref>
###xml 1002 1005 981 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Manel1">[9]</xref>
###xml 1007 1011 986 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Volpe1">[10]</xref>
###xml 1013 1017 992 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Wilson1">[11]</xref>
###xml 1150 1154 1125 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Duan1">[12]</xref>
###xml 1156 1160 1131 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Komura1">[13]</xref>
###xml 1162 1166 1137 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Kurasawa1">[14]</xref>
###xml 1168 1172 1143 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Murata1">[15]</xref>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 1112 1120 <span type="species:ncbi:9606">patients</span>
In this line the Th1/Th2 paradigm has been investigated by studying the presence of Th1 (IL-12, IFNgamma) and Th2 (IL-4, IL-13 and IL-10) associated cytokines in the circulation, in circulating cells and in the skin of SSc patients. Driven by opposing findings, these studies led controversy whether these Th1/Th2 profiles could explain the pathogenesis of SSc. The recognition of IL-17 producing T cells (Th17) has opened novel pathways to explain several features of SSc. In general, T cell priming by professional antigen presenting cells is tuned by inflammatory mediators, including TGFbeta, IL-6 and IL-12. The combination of these cytokines determines the ultimate fate of naive T cells. For instance, TGFbeta alone up regulates FoxP3 expression, a marker for T regulatory cells. In contrast, accumulating evidence suggests that TGFbeta in combination with IL-1alpha, IL-6 or IL-23 drives the expression of RORgammat, a proliferation factor specific for the recently identified Th17 subset [8], [9], [10], [11]. Intriguingly, IL-23, IL-1alpha and IL-17 have been found increased in the circulation of SSc patients compared to healthy controls [12], [13], [14], [15]. Together, these observations suggest the potential for skewing of the Th17 axis in SSc.
###end p 10
###begin p 11
###xml 589 593 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Ferber1">[16]</xref>
###xml 714 718 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Becher1">[17]</xref>
###xml 720 724 716 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Cua1">[18]</xref>
###xml 809 813 805 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Chabaud1">[19]</xref>
###xml 834 838 830 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Lock1">[20]</xref>
###xml 867 871 863 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Fujino1">[21]</xref>
###xml 883 887 879 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Wilson1">[11]</xref>
###xml 924 928 920 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Jandus1">[22]</xref>
###xml 1173 1177 1169 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Fossiez1">[23]</xref>
###xml 1179 1183 1175 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Ye1">[24]</xref>
###xml 1347 1351 1343 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Chakir1">[25]</xref>
###xml 1481 1485 1477 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Braun1">[26]</xref>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
###xml 774 782 <span type="species:ncbi:9606">patients</span>
###xml 1216 1224 <span type="species:ncbi:405018">cardinal</span>
Th17 cells are characterized by the production of IL-17A (IL-17) and are thought to clear extracellular pathogens not effectively cleared by either Th1 or Th2 cells. To this aim, Th17 cells appear at sites of inflammation with rapid kinetics and possibly bridge the gap between innate and adaptive immunity by attracting other Th cells to the inflammatory site. Various recent studies have emerged suggesting that Th17 cells are essential in autoimmune diseases. First, mice deficient for the Th1 effector cytokine IFNgamma develop enhanced experimental autoimmune encephalomyelitis (EAE) [16], and the absence of IL-23, results in a lack of Th17 cells and protection from EAE and collagen-induced arthritis (CIA) [17], [18]. Second, IL-17 has been found to be increased in patients with rheumatoid arthritis [19], multiple sclerosis [20], inflammatory bowel disease [21], psoriasis [11] and seronegative spondylarthritides [22]. IL-17 has been involved in many pathological features that play a role in SSc pathology including the secretion of pro-inflammatory cytokines, the recruitment of monocytes and the triggering of granulocyte-macrophage colony-stimulating factor [23], [24]. In light of fibrosis being the cardinal feature of SSc, it is interesting to note that IL-17 has also been implicated in fibrosis of the basal membrane in asthma [25] and the control of inflammatory response after bleomycin-induce lung injury, a model often exploited to study pulmonary fibrosis [26].
###end p 11
###begin p 12
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
###xml 599 606 <span type="species:ncbi:9606">patient</span>
###xml 1171 1179 <span type="species:ncbi:9606">patients</span>
To address the possible role of IL17 in SSc, we investigated Th17 cell frequency in the circulation of SSc patients, and the expression of key cytokine regulators and markers of T cell phenotypes, IFNgamma and TGFbeta. Because there are two clinically distinct forms of systemic sclerosis and at least one of these forms evolves over time, we evaluated Th17 cell frequency and cytokine expression in three subgroups: patients with early compared to late diffuse cutaneous SSc and patients with limited cutaneous SSc. We found that circulating Th17 cells are significantly increased in all three SSc patient subsets compared to healthy controls. In addition, together with the expression of IL-17, clinical SSc phenotypes were associated with specific patterns of intracellular expression of TGFbeta and IFNgamma. Together these data indicate that T cell priming in SSc is skewed towards the Th17 axis, which together with intracellular staining for TGFbeta and IFNgamma provide a novel markers of SSc phenotypes. Importantly, circulating levels of IL-17 were undetectable whereas the Th17 inducing cytokines IL-6 and IL-23 levels were increased in the circulation of SSc patients.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Study population
###end title 14
###begin title 15
###xml 11 19 11 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
Cell-based In vitro experiments
###end title 15
###begin p 16
###xml 105 106 105 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 106 113 106 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 106 113 106 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005903-t001"><bold>Table 1</bold></xref>
###xml 113 114 113 114 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 228 232 228 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-1">[27]</xref>
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-LeRoy1">[28]</xref>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 234 242 <span type="species:ncbi:9606">Patients</span>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 613 621 <span type="species:ncbi:9606">patients</span>
Thirty-six patients presenting to the Arthritis Center, Boston Medical Center were included in the study (Table 1). All of the patients met the American College of Rheumatology preliminary criteria for the classification of SSc [27]. Patients were subdivided as having limited cutaneous SSc (lcSSc, n = 12) or diffuse cutaneous SSc (dcSSc, n = 24) on the basis of the extent of their skin involvement [28]. A further subdivision was made between early dcSSc (n = 11) and late dcSSc (n = 13) based upon the duration of disease, defining early dcSSc as patients having a disease duration <2 years and late dcSSc as patients having a disease duration longer than 3 years. As a comparator group 14 healthy controls were studied. Treatment was investigated 6 months before the study.
###end p 16
###begin title 17
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of patients included in in vitro assays.
###end title 17
###begin p 18
0.03.
###end p 18
###begin title 19
Measurement of circulating cytokines
###end title 19
###begin p 20
###xml 241 249 233 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
For the measurement of circulating levels of TNFalpha, IL-6 and IFNgamma plasma from healthy controls (n = 28) and 177 SSc patients (lSSc n = 110, ldSSc n = 34, edSSc n = 33) from the Boston University Area (similar to those included in the in vitro studies), the Radboud University Nijmegen Medical Center area (RUMC) and Lund University Hospital area were analyzed. Blood and plasma samples were obtained with approval by written informed consent under Institutional Review Board approval protocols at all three academic centers involved.
###end p 20
###begin title 21
Monoclonal antibodies
###end title 21
###begin p 22
###xml 177 182 <span type="species:ncbi:10090">mouse</span>
###xml 219 224 <span type="species:ncbi:9606">human</span>
###xml 515 520 <span type="species:ncbi:10090">mouse</span>
###xml 521 524 <span type="species:ncbi:10116">rat</span>
For immunostaining and analysis by fluorescence-activated cell sorting (FACS), we used phycoerythrin (PE), allophycocyanin (APC) and fluorescein isothiocynate (FITC) conjugated mouse monoclonal antibodies (mAb) against human CD4, CD8, GITR, CD69, IL-23R, CD45Ro, CD45Ra, and CD25 (Miltenyi Biotec Inc., CA, USA). Intracellular staining of CD45Ro, CD45Ra or CD25+ cells for IL-17, TGFbeta and IFNgamma was performed using the intracellular staining procedure according to the manufacturer's protocols. Corresponding mouse/rat isotype controls were included in all analyses.
###end p 22
###begin title 23
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Isolation of PBMCs, CD3+ cells and flow cytometry
###end title 23
###begin p 24
PBMCs were isolated from heparinized venous blood by using density-gradient centrifugation over Ficoll-Paque (Amersham Bioscience). Next, CD3+ cells were isolated from PBMCs using CD3 microbeads according to manufacturer's protocol (Miltenyi Biotec). After isolation, cells were directly transferred into RPMI 1640 media supplemented with 2 nM L-glutamine, 100 U/microL/ml penicillin/streptomycin (Life technologies), and 10% FBS (BioWhitacker) in 96-well U-bottom plates (Nunc). For flowcytometric analysis, CD3+ were kept on ice and washed extensively with citrated PBS containing 1% FCS. 10 microl of FITC, APC or PE- conjugated antibody was added and incubated on ice for 20 min. 300 microl FACS buffer was added and T cells were pelleted, resuspended in 200 microl buffer. Thereafter, cells were washed in buffer, fixed with 2% formaldehyde, washed again in buffer and stored at 4degreesC. The cells were analyzed using a LSRII FACScan flow cytometer (BD Biosciences) and data were processed using FlowJo software.
###end p 24
###begin title 25
Measurement of intracellular and circulating cytokines
###end title 25
###begin p 26
###xml 74 78 67 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 501 505 485 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Abe1">[29]</xref>
Intracellular expression of IL-17, IFNgamma and TGFbeta in CD4 and/or CD25high cells was investigated using monoclonal antibodies obtained from BD Bioscience, NJ, USA. After the staining protocol, cells were fixed with 2% formaldehyde, stored at 4degreesC and analyzed on flow cytometer the next day. Circulating and supernatant cytokine levels were measured and analyzed with the Bio-Plex system (Bio-Rad). TGFbeta in supernatants was measured using the sensitive assay first described by Abe et al. [29] whereas IFNgamma and IL-17 were measured using the Luminex platform. The sensitivity of the cytokine assay was <5 pg/ml for all cytokines measured.
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
Values are shown throughout the paper as mean+/-sem. Proportions of lymphocyte subpopulations were compared using the Student's t test for normally or not normally distributed population where appropriate. Relationships between different values were examined using Pearson's correlation coefficient and Spearman's rank correlation tests. Difference between groups were calculated using the Mann-Withney U test. All statistical analyses were performed using Graphpad Prism (GraphPad Prism 4.0 by Graph Pad software Inc.).
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
###xml 30 38 <span type="species:ncbi:9606">patients</span>
CD4 positive T cells from SSc patients display an activated phenotype
###end title 30
###begin p 31
###xml 182 185 182 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Gustafsson1">[2]</xref>
###xml 187 191 187 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Gorla1">[30]</xref>
###xml 487 496 487 496 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">figure 1a</bold>
###xml 487 496 487 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005903-g001"><bold>figure 1a</bold></xref>
###xml 496 497 496 497 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 678 679 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 763 764 763 764 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 764 773 764 773 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">figure 1b</bold>
###xml 764 773 764 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005903-g001"><bold>figure 1b</bold></xref>
###xml 773 774 773 774 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 1229 1230 1229 1230 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 1230 1239 1230 1239 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">figure 1b</bold>
###xml 1230 1239 1230 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005903-g001"><bold>figure 1b</bold></xref>
###xml 1239 1252 1239 1252 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, left panel)</bold>
###xml 1691 1692 1691 1692 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 1692 1701 1692 1701 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">figure 1b</bold>
###xml 1692 1701 1692 1701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005903-g001"><bold>figure 1b</bold></xref>
###xml 1701 1714 1701 1714 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> right panel)</bold>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
###xml 849 857 <span type="species:ncbi:9606">patients</span>
###xml 902 910 <span type="species:ncbi:9606">patients</span>
###xml 1047 1055 <span type="species:ncbi:9606">patients</span>
###xml 1119 1127 <span type="species:ncbi:9606">patients</span>
###xml 1184 1192 <span type="species:ncbi:9606">patients</span>
###xml 1585 1593 <span type="species:ncbi:9606">patients</span>
Previous reports have described an increased CD4/CD8 ratio in SSc patients compared with healthy controls, however, recent markers permit a more refined analysis of T cell phenotype [2], [30]. Since effector T cells, suggested to be involved in SSc, arise from the CD4+ T cells, we first investigated T cell phenotype and activation. Consistent with previous studies, healthy controls (n = 13) displayed a considerably lower CD4+/CD8+ ratio than that observed in SSc patients (P<0.0001, figure 1a). We next investigated whether CD4+ cells in SSc patients expressed T cell activation markers, CD69 and GITR. Indeed, SSc patients on average expressed significantly higher levels (P<0.0001) of CD69 on CD4+ effector T cells compared with those from healthy controls (figure 1b). In contrast, CD69 expression was increased on CD8+ cells only from those patients with the edcSSc, but not on CD8+ cells from patients with lcSSc or ldcSSc (P<0.001). The expression of GITR displayed a similar pattern being higher on CD4+ cells from all subgroups of SSc patients compared to controls (P<0.001). Highest expression was seen in patients with edcSSc, with progressively less expression seen in patients with ldcSSc and lcSSc, respectively (figure 1b, left panel). These observations prompted us to further study the expression of these activation markers on memory (CD45Ro) and naive T cells (CD45Ra), since CD45Ro cells were previously found to be the main producers of IL-17. Interestingly, the expression of CD69 was significantly higher on both CD45Ro and CD45Ra positive T cells in all SSc patients compared with healthy controls, suggesting that both these cell populations are activated in SSc (figure 1b right panel).
###end p 31
###begin title 32
###xml 4 12 <span type="species:ncbi:9606">patients</span>
SSc patients have more and more activated CD4+ T cells compared to healthy controls.
###end title 32
###begin p 33
###xml 132 140 <span type="species:ncbi:9606">patients</span>
###xml 745 753 <span type="species:ncbi:9606">patients</span>
Panel A depicts the percentage of CD4+ and CD8+ cells in the whole T cell pool (CD3+ cells) from healthy controls (n = 14), and SSc patients with the lcSSc (n = 12), ldcSSc (n = 11) and edcSSc (n = 13) phenotype. The CD3+ cells were isolated using MACS bead isolation after which CD4 and CD8 positivity was analyzed using flow cytometry. Panel B (left) depicts the percentage of CD4+ and CD8+ cells that were double-positive for the T cell activation markers CD69 and GITR. For this aim a representative individual from each group was selected. In the right panel, the percentage of CD4-CD69, CD8-CD69, CD4-GITR, CD8-GITR, CD45Ro-CD69 and CD45Ra-CD69 double positive cells is presented over the whole group of healthy donors (n = 14) and/or SSc patients (n = 36).
###end p 33
###begin title 34
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Th17 cells are more frequent in SSc patients and IL-17 in combination with IFNgamma and TGFbeta expression in T cells discriminates SSc subsets
###end title 34
###begin p 35
###xml 426 429 426 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Annunziato1">[8]</xref>
###xml 431 435 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Murata1">[15]</xref>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Bettelli1">[31]</xref>
###xml 443 447 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Stockinger1">[32]</xref>
###xml 577 588 577 588 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(P&lt;0.0001, </bold>
###xml 588 597 588 597 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">figure 2a</bold>
###xml 588 597 588 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005903-g002"><bold>figure 2a</bold></xref>
###xml 597 598 597 598 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 1058 1069 1058 1069 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(P&lt;0.0001, </bold>
###xml 1069 1078 1069 1078 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2b</bold>
###xml 1069 1078 1069 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005903-g002"><bold>Figure 2b</bold></xref>
###xml 1078 1079 1078 1079 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
###xml 732 740 <span type="species:ncbi:9606">patients</span>
###xml 1036 1044 <span type="species:ncbi:9606">patients</span>
###xml 1199 1207 <span type="species:ncbi:9606">patients</span>
###xml 1389 1397 <span type="species:ncbi:9606">patients</span>
These observations showing activated T cells in patients with SSc and recent findings of increased circulating levels of IL-17 and IL-23 in patients with SSc, led us to examine the expression of the IL-23 receptor (IL-23R) on T effector cells. Since it was recently demonstrated that IL-23 is pivotal in the survival of Th17 cells, increased expression of IL-23R might lead to enhanced Th17 cell survival in patients with SSc [8], [15], [31], [32]. Intriguingly, the expression of IL-23R was markedly higher on CD3+, CD45Ro+ and CD45Ra cells from all SSc patients investigated (P<0.0001, figure 2a). Notably, increased IL23R expression was observed on CD4+ T cells of patients with both limited and diffuse cutaneous SSc, including patients with ldSSc. Next, we investigated the intracellular expression of IL-17 in CD45Ro and CD45Ra cells. Consistent with the increased expression of IL-23R and markers of activation (CD69 and GITR expression), the number of CD45Ro cells that co-expressed IL-17 was significantly increased in all SSc patients investigated (P<0.0001, Figure 2b). As previously described, CD45Ra cells from healthy controls did not express IL-17. In contrast, CD45Ra cells from SSc patients showed increased numbers of IL-17 expressing cells that reached almost similar levels as CD45Ro cells However, the mean fluorescence intensity (MFI) of IL-17 in CD45Ro cells in SSc patients was clearly increased compared to that observed in CD45Ra cells.
###end p 35
###begin title 36
###xml 4 12 <span type="species:ncbi:9606">patients</span>
SSc patients express high levels of IL-17-positive T cells and the co-presence of IL-17 with either IFNgamma, IFNalpha or TGFbeta reflects SSc phenotype.
###end title 36
###begin p 37
###xml 797 801 783 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1081 1082 1063 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1100 1101 1082 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1119 1120 1101 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
###xml 1042 1050 <span type="species:ncbi:9606">patients</span>
Panel A presents the percentage of IL-23R positive cells in the CD4+ positive pool of T cells (left panel) and CD45Ro and CD45Ra positive cells (right panel) from healthy controls (n = 14), and SSc patients with the lcSSc (n = 12), ldcSSc (n = 11) and edcSSc (n = 13) phenotype. Panel B shows the mean intracellular expression level of IL-17, IFNgamma and TGFbeta in CD4+ cells from each a representative individual from each tested group (left side). On the right side, the mean percentage of CD45Ro-positive or CD45Ra-positive cells that express IL-17, IFNgamma or TGFbeta and the mean intensity thereof are presented for the whole group of healthy controls (n = 14), and SSc patients with the lcSSc (n = 12), ldcSSc (n = 11) and edcSSc (n = 13) phenotype. Panel C depicts the percentage of CD25high cells that co-express IL-17 in healthy controls and different SSc phenotypes (* represents a p-value<0.01). Panel D represents the level of cytokines (IL-17 and IFNgamma) spontaneously secreted by CD3+ T cells from healthy controls and SSc patients after 24 hrs of incubation. * P-value<0.0001, ** P-value<0.002, *** P-value<0.004.
###end p 37
###begin p 38
###xml 863 864 849 850 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 864 871 850 857 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 864 871 850 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005903-t002"><bold>Table 2</bold></xref>
###xml 871 872 857 858 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
###xml 405 413 <span type="species:ncbi:9606">patients</span>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
###xml 667 675 <span type="species:ncbi:9606">patients</span>
###xml 742 750 <span type="species:ncbi:9606">patients</span>
To further investigate cytokine expression of T cell from SSc patients, we investigated the expression of TGFbeta and IFNgamma other cytokines that have been implicated in SSc pathogenesis. Comparison of the cytokine expression by T cells from patients with the different SSc phenotypes revealed a clearly distinct pattern. For instance, IFNgamma was highly expressed by both CD45Ro and CD45Ra cells from patients with limited SSc, was almost absent in CD45Ro cells from SSc patients with diffuse SSc and expressed at intermediate levels by CD45Ra cells from diffuse patients. In contrast, the expression of TGFbeta was increased in both CD45Ro and CD45Ra cells from patients with limited and late diffuse SSc but was normal in early diffuse patients. Based on these observations we propose that certain cytokine patterns are associated with certain SSc subtypes (Table 2).
###end p 38
###begin title 39
Cytokine expression pattern in SSc clinical phenotypes.
###end title 39
###begin p 40
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Koenen1">[33]</xref>
###xml 457 461 457 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 645 654 645 654 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">figure 2c</bold>
###xml 645 654 645 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005903-g002"><bold>figure 2c</bold></xref>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
Previously, we demonstrated that SSc patients have increased levels of circulating T regulatory cells (submitted for publication). Recently, two elegant studies revealed that neither Tregs nor Th17 cells are terminally differentiated but, under pressure of several cytokines or other immune cells, could switch phenotype [33]. Since this could be an explanation for concurrent increased expression both of Tregs and Th17 in SSc, we investigated whether CD25high expressing cells (Tregs) co-expressed IL-17. Indeed, significant higher numbers of CD25high/IL-17-positive cells were observed in SSc patients compared with healthy controls (P<0.01, figure 2c).
###end p 40
###begin p 41
###xml 497 506 485 494 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">figure 2d</bold>
###xml 497 506 485 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005903-g002"><bold>figure 2d</bold></xref>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 299 307 <span type="species:ncbi:9606">patients</span>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
###xml 709 717 <span type="species:ncbi:9606">patients</span>
To further extend and confirm our results showing increased intracellular expression of IL-17 and IFNgamma in SSc, we next measured the levels of IL-17 and IFNgamma in the supernatant of CD3+ T cells isolated from healthy controls (n = 5), lcSSc patients (n = 5), ldcSSc patients (n = 5) and edcSSc patients (n = 5). Consistent with intracellular cytokine expression, T cells from all three clinical phenotypes secreted high levels of IL-17 and IFNgamma compared to T cells from healthy controls (figure 2d). The pattern of altered secretion was also similar, with the highest levels of IFNgamma secreted by T cells from patients with lcSSc, while the highest levels of IFNgamma were secreted by T cells from patients with early diffuse SSc.
###end p 41
###begin title 42
###xml 4 12 <span type="species:ncbi:9606">patients</span>
SSc patients have normal levels of IL-17 but increased levels of Th17 promoting cytokines IL-1alpha, IL-23 and IL-6
###end title 42
###begin p 43
###xml 99 103 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Murata1">[15]</xref>
###xml 705 712 705 712 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 3</bold>
###xml 705 712 705 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005903-t003"><bold>Table 3</bold></xref>
###xml 714 723 714 723 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3a</bold>
###xml 714 723 714 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005903-g003"><bold>Figure 3a</bold></xref>
###xml 1032 1033 1016 1017 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 1033 1044 1017 1028 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3b&#8211;d</bold>
###xml 1033 1044 1017 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005903-g003"><bold>Figure 3b&#8211;d</bold></xref>
###xml 1044 1045 1028 1029 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 405 413 <span type="species:ncbi:9606">patients</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
###xml 769 777 <span type="species:ncbi:9606">patients</span>
###xml 1201 1209 <span type="species:ncbi:9606">patients</span>
It has previously been reported that IL-17 levels are increased in the circulation in SSc patients [15]. A major limitation of these studies was the small sample size. This, together with our experience that circulating IL-17 is very difficult to detect in other autoimmune disorders such as rheumatoid arthritis, we investigated the levels of IL-17 and IL-17 promoting cytokines in a large cohort of SSc patients (n = 177) consisting out of 110 patients with LSSc, 34 with ldSSc and 33 with the edSSc phenotype. As a comparator group we used 28 healthy controls. When comparing the level of IL-17 in SSc patients and healthy controls, IL-17 could only be detected in a minority of the samples (9 of 177; Table 3, Figure 3a) and was not detected more frequently in SSc patients compared to controls. In contrast, the levels of IL-6 (53.6+/-9.7 vs. 5.4+/-3.4, P<0.0001), IL-1alpha (83.2+/-11.2 vs. 1.2+/-1.1, P<0.002) and IL-23 (49.1+/-7.3 vs. 5.3+/-0.6, P = 0.003) were significantly higher in SSc as a whole compared with controls (Figure 3b-d). Subgroup analysis revealed that IL-6 and IL-23 levels were equally distributed among SSc phenotypes whereas IL-1alpha was significantly increased in lSSc patients (P<0.001) only. An association between clinical characteristics including the presence of autoantibodies, disease duration and/or pulmonary involvement was not observed (data not shown).
###end p 43
###begin title 44
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Increased level of Th17 inducing cytokines in the circulation of SSc patients.
###end title 44
###begin p 45
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Panel A depicts the presence of IL-17 in the circulation of SSc patients and healthy controls. Panel B, C and D represents the levels of IL-6, IL-1alpha and IL-23, respectively. The circulating levels of IL-17, IL-1alpha and IL-23 was measured by ELISA whereas IL-6 was studied by Bioplex assays.
###end p 45
###begin title 46
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of patients used for measurement of circulating cytokines.
###end title 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 441 449 <span type="species:ncbi:9606">patients</span>
###xml 595 603 <span type="species:ncbi:9606">patients</span>
We show here that patients with SSc have strikingly increased frequencies of circulating Th17 cells. In addition, the combined analysis of intracellular IL-17 with the expression of IFNgamma or TGFbeta revealed a pattern among patients that correlated with the different clinical SSc phenotypes. In line with these observations, levels of Th17 inducing cytokines IL-6, IL-1alpha and IL-23 were significantly higher in the circulation of SSc patients compared to controls, although circulating IL-17 was not detectable. Similar to our observations, the measurement of IL-17 in the circulation of patients with rheumatoid arthritis and psoriasis, two conditions in which IL-17 play a pivotal role in local pathology, was very disappointing. Therefore, it is tempting to speculate that IL-17 might be an important cytokine locally in SSc.
###end p 48
###begin p 49
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 261 269 <span type="species:ncbi:9606">Patients</span>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 440 448 <span type="species:ncbi:9606">patients</span>
In our study all SSc patients had increased frequencies of IL-17 positive cells and T cells cultured from SSc patients showed high spontaneous production of IL-17. However, co-expression of IFNgamma and TGFbeta together with IL-17 distinguished SSc phenotypes. Patients with lcSSc expressed IL-17, IFNgamma and TGFbeta at the highest levels. In particular, T cells from these patients expressed higher levels of intracellular IFNgamma than patients with edcSSc. Interestingly, in the lcSSc subgroup circulating levels of IL-1alpha were significantly higher compared to other SSc phenotypes and healthy controls, whereas IL-6 and IL-23 levels were elevated but comparable in all SSc subgroups. Perhaps, higher IL-1alpha levels skew the balance to more IL-17/IFNgamma double positive T cells.
###end p 49
###begin p 50
###xml 660 664 653 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Gerosa1">[34]</xref>
###xml 967 971 960 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Akira1">[35]</xref>
###xml 1015 1019 1008 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Roelofs1">[36]</xref>
###xml 1444 1448 1437 1441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Roelofs2">[37]</xref>
###xml 858 866 <span type="species:ncbi:9606">patients</span>
###xml 1434 1442 <span type="species:ncbi:9606">patients</span>
###xml 1799 1807 <span type="species:ncbi:9606">patients</span>
The potential involvement of IL-17 in various autoimmune diseases has sparked research aimed at the identification of the forces driving Th17 priming. To date, accumulating evidence point towards the essential role of DCs in orchestrating Th17 priming by the production of the driving factors for Th17 development, such as TGFbeta, IL-1alpha, IL-6 and IL-23. More recently, it has become clear that Toll-like receptor mediated DC activation is also implicated. In this light Gerosa and co-workers demonstrated that the combination of specific Toll-like receptor (TLR) ligands dramatically stimulated IL-23 production and skews the immune response towards Th17 [34]. Although the role of TLRs in SSc has not been subjected to extensive research, our observations suggest a possible role for TLRs as a stimulus for the increased numbers of Th17 cells in these patients. TLR are critical for the innate immune response and bridge the innate and adaptive immune response [35]. Many ligands have been described for TLRs [36]. For TLR2 and TLR4 both exogenous (derived from microorganisms) and endogenous (originating from "self" tissues) have been identified. In contrast, ligands identified for the intracellular TLR3, TLR7, TLR8 and TLR9 mainly comprise exogenous ligands including double and single stranded RNA and CPG DNA. In this light it is interesting that several endogenous ligands for TLR4 are present in the plasma of some SSc patients ([37], unpublished results). We are currently investigating the nature of endogenous TLR ligands in different SSc phenotypes that could help to explain the observed differences with respect to co-expression of several cytokines in conjunction with IL-17. Recent observations from our group indicate an aberrant TLR responses in SSc that are distinct among patients having lcSSc, ldcSSc and edcSSc (manuscript submitted).
###end p 50
###begin p 51
###xml 271 275 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Wilson1">[11]</xref>
###xml 380 384 380 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005903-Jandus1">[22]</xref>
###xml 84 90 <span type="species:ncbi:9606">humans</span>
Little is known about the differentiation and maturation of IL-17 positive cells in humans. In contrast with the initial reports, we demonstrate that the Th17 phenotype is not confined to CD4+ effector cells but also includes a substantial number of naive cells (CD45Ra) [11]. The latter is in line with a recent report investigating Th17 cells in seronegative spondylarthropathy [22]. As explained in this report, potential differences between studies could be explained by slightly differences in isolation protocols. However, an important other explanation might be that the factors that drive Th17 among different diseases differ also with respect to the CD4+ subpopulations that are activated.
###end p 51
###begin p 52
Taken together, although the underlying mechanisms that explain the distinct patterns of intracellular cytokine expression among SSc phenotypes need to be identified, these patterns suggest distinct immune dysregulation in dcSSc versus lcSSc and in early versus late disease in dcSSc. These insights open novel avenues for research aimed at identifying pathogenic pathways and therapeutic targets.
###end p 52
###begin p 53
We are indebted to Mike Dimarzio who carefully performed the functional assays to measure TGFbeta.
###end p 53
###begin title 54
References
###end title 54
###begin article-title 55
###xml 184 192 <span type="species:ncbi:9606">patients</span>
Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis.
###end article-title 55
###begin article-title 56
Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis.
###end article-title 56
###begin article-title 57
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis.
###end article-title 57
###begin article-title 58
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Early T cell activation in the skin from patients with systemic sclerosis.
###end article-title 58
###begin article-title 59
###xml 115 123 <span type="species:ncbi:9606">patients</span>
Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis.
###end article-title 59
###begin article-title 60
T cells expressing allograft inflammatory factor 1 display increased chemotaxis and induce a profibrotic phenotype in normal fibroblasts in vitro.
###end article-title 60
###begin article-title 61
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis.
###end article-title 61
###begin article-title 62
###xml 38 43 <span type="species:ncbi:9606">human</span>
Phenotypic and functional features of human Th17 cells.
###end article-title 62
###begin article-title 63
###xml 23 28 <span type="species:ncbi:9606">human</span>
The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat.
###end article-title 63
###begin article-title 64
###xml 128 133 <span type="species:ncbi:9606">human</span>
A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses.
###end article-title 64
###begin article-title 65
###xml 46 51 <span type="species:ncbi:9606">human</span>
Development, cytokine profile and function of human interleukin 17-producing helper T cells.
###end article-title 65
###begin article-title 66
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma.
###end article-title 66
###begin article-title 67
###xml 34 42 <span type="species:ncbi:9606">Patients</span>
Increased Serum Interleukin 23 in Patients with Systemic Sclerosis.
###end article-title 67
###begin article-title 68
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Increased interleukin-17 production in patients with systemic sclerosis.
###end article-title 68
###begin article-title 69
Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease?
###end article-title 69
###begin article-title 70
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE).
###end article-title 70
###begin article-title 71
Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12.
###end article-title 71
###begin article-title 72
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.
###end article-title 72
###begin article-title 73
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium.
###end article-title 73
###begin article-title 74
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.
###end article-title 74
###begin article-title 75
Increased expression of interleukin 17 in inflammatory bowel disease.
###end article-title 75
###begin article-title 76
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides.
###end article-title 76
###begin article-title 77
T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.
###end article-title 77
###begin article-title 78
###xml 65 70 <span type="species:ncbi:9606">human</span>
Fluorescent microsphere-based readout technology for multiplexed human single nucleotide polymorphism analysis and bacterial identification.
###end article-title 78
###begin article-title 79
Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression.
###end article-title 79
###begin article-title 80
IL-17 producing gammadelta T cells are required for a controlled inflammatory response after bleomycin-induced lung injury.
###end article-title 80
###begin article-title 81
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
###end article-title 81
###begin article-title 82
Criteria for the classification of early systemic sclerosis.
###end article-title 82
###begin article-title 83
An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct.
###end article-title 83
###begin article-title 84
###xml 73 81 <span type="species:ncbi:9606">patients</span>
CD4+ and CD8+ subsets: naive and memory cells in the peripheral blood of patients with systemic sclerosis.
###end article-title 84
###begin article-title 85
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.
###end article-title 85
###begin article-title 86
Differentiation and function of Th17 T cells.
###end article-title 86
###begin article-title 87
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells.
###end article-title 87
###begin article-title 88
###xml 75 80 <span type="species:ncbi:9606">human</span>
Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells.
###end article-title 88
###begin article-title 89
Toll-like receptor signalling.
###end article-title 89
###begin article-title 90
The orchestra of Toll-like receptors and their potential role in frequently occurring rheumatic conditions.
###end article-title 90
###begin article-title 91
The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells.
###end article-title 91
###begin p 92
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 92
###begin p 93
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The Post-doctoral program (T.R.) was funded by the Niels-Stensen Foundation from The Netherlands. The work presented here was partly funded by the VIDI laureate (T.R) from the Dutch Organization of Research (NWO). Support was also provided by grants to R.L. from the National Institutes of Health, (NIAMS U01AR055063) and an unrestricted grant from the American Society for Scleroderma Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 93

